Trial Profile
An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Acerta Pharma
- 21 Jun 2020 Results (N=1040) of pooled analysis from nine clinical studies: ACE-CL-007, ACE-CL-309, ACE-CL-001, 15-H-0016, ACE-LY-002, ACE-LY-003, ACE-LY-004, ACE-MY-001, ACE-WM-001 assessing safety profile of acalabrutinib monotherapy in multiple B-cell malignancies presented at the 25th Congress of the European Haematology Association
- 18 Jun 2019 Status changed from active, no longer recruiting to completed.
- 17 Dec 2018 Results of population pharmakoinetics of Acalabrutinib and its Active Metabolite using data from this and other 12 studies, published in the Clinical Pharmacokinetics